Barclays’s Seaport Therapeutics SPTX Stock Holding History

Barclays’s Portfolio SPTX Stock Details SPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$113K	Buy	5,600 +4,763	+569%	+$106K	﹤0.01%	4252
2026 Q2	$18.2K	Buy	+837	New	+$14.7K	﹤0.01%	4603

Other funds holding SPTX

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Barclays's SPTX Position: Q3 2026 in Review

Barclays increased its Seaport Therapeutics (SPTX) stake by 569% in Q3 2026, buying an estimated $106K and bringing the position to 5,600 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #4252.

Barclays first reported a position in SPTX in Q2 2026 and has held it in 2 quarters since. 13 funds tracked by Wall St. Rank hold SPTX as of Q3 2026.

Barclays held 5,600 shares of Seaport Therapeutics worth $113K as of Q3 2026.
Barclays bought 4,763 Seaport Therapeutics shares in Q3 2026, an estimated $106K.
Seaport Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4252 holding.
Barclays first reported a position in Seaport Therapeutics in Q2 2026 and has held it in 2 quarters since.
13 funds tracked by Wall St. Rank held Seaport Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.